Joe Kiani Provides Keynote at the 5th Annual Global Ministerial Summit on Patient Safety
27.2.2023 23:33:00 EET | Business Wire | Press release
In a keynote address at the Fifth Global Ministerial Summit on Patient Safety, Joe Kiani, founder of the Patient Safety Movement Foundation (PSMF), called for hospitals around the world to show greater transparency in reporting medical errors and preventable deaths. He also stressed the importance of aligned incentives, so providers are paid on quality of care rather than quantity and the adoption of Actionable Evidence-Based Practices addressing the known causes of harm.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230227005765/en/
Joe Kiani Provides Keynote at the 5th Annual Global Ministerial Summit on Patient Safety (Photo: Business Wire)
“We need not just access to healthcare, it has to be safe, it has to be dignified,” said Kiani. “To get there, we have to create self-governing actions. If we can agree on the medical errors that can be prevented through evidence-based practices, those then can be tracked by every hospital. And they could report every year, every quarter, on their website publicly, the number of harms they have for each of those errors.”
Transparency, Kiani argued, is critical because publicly revealing data on preventable medical errors helps to accelerate the pace of change.
In countries where healthcare is at least partially subsidized by the government, Kiani suggested introducing major financial incentives for hospitals to be more transparent and active in patient safety by implementing evidence-based practices for preventing errors.
“In my country, half of the care is paid for by the Government. Medicare and Medicaid pays for more than half the care in every hospital,” he said. “So therefore, they could mandate that to get that reimbursement, they want transparency, and that they will tie their performance to the payment. So if hospitals have zero medical errors, zero preventable deaths, they don't have to do anything. But if someone is harmed, and those evidence-based practices were not in place, they should not get paid. This becomes a way that every board of directors of every hospital will expect their management to implement evidence-based practices.”
As an example of how this can work, Kiani cited his time on the board of directors of Children's Hospital of Orange County (CHOC), California. “When I began at CHOC, I was happy to see they were looking at quality,” he said. “They were looking at medical errors, but they were comparing themselves to their colleagues, and if they were lower in error rate than others, that was considered a job well done. And I challenged them that shouldn't the goal be zero? To their credit, they accepted the challenge, and they went one step further, they tied the bonuses of the faculty to zero. Something incredible occurred at the next meeting, we went from hoping for zero, to planning for zero.”
“I want you all to take action out of kindness!” concluded Joe Kiani.
The Global Ministerial Summit on Patient Safety is an annual event that brings together ministers, high-level representatives, and experts from around the world. This year’s summit was hosted by President Alain Berset and the distinguished speakers included; Tedros Adhanom Ghebreyesus, Director-General, World Health Organization; Professor Didier Pittet, Professor of Medicine at the University of Geneva; Dr. Anthony Staines, Patient Safety Program Director of Vaud Hospital Federation in Switzerland; Professor Dr. Phil Lauren Clark, Professor of Implementation Science in Health Care; and Professor Sir Liam Donaldson, WHO Patient Safety Envoy.
This year the Patient Safety Movement Foundation will hold its 10th Annual World Patient Safety, Science & Technology Summit on June 1st and 2nd in Newport Beach, California.
ABOUT THE PATIENT SAFETY MOVEMENT FOUNDATION
In 2012, Joe Kiani founded the non-profit Patient Safety Movement Foundation (PSMF) to eliminate preventable medical errors in hospitals. His team worked with patient safety experts from around the world to create Actionable Evidence-Based Practices (AEBP) that address the top challenges. The AEBP is available without charge to hospitals online. Hospitals are encouraged to make a formal commitment to ZERO preventable deaths, and healthcare technology companies are asked to sign the Open Data Pledge to share their data so that predictive algorithms that can identify errors before they become fatal can be developed. The Foundation's annual World Patient Safety, Science & Technology Summit brings together all stakeholders, including patients, healthcare providers, medical technology companies, government employers, and private payers. The PSMF was established through the support of the Masimo Foundation for Ethics, Innovation, and Competition in Healthcare. For more information, please visit psmf.org.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230227005765/en/
Contact information
Patient Safety Movement Foundation
Irene Mulonni, irene@mulonni.com | (858) 859-7001
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 14:42:00 EEST | Press release
2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (Photo: AETOSWire) Net profit from the Group’s businesses increased by 2,301% year-on-year (YoY), driven by the consolidation of Tendam and the mega-merger to form 2PointZero Group, and growth was also supported by new investments in African financial services, entry into the European packaging markets, and steady operational progress across all verticals, bringing the total reported net profit to AED 7.7 billion. Through continued operational integr
Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
Half-Year Report on SES’s Liquidity Contract31.7.2026 08:30:00 EEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
SES: Disclosure of Share Buyback Transactions31.7.2026 08:30:00 EEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
